*Pasithea Therapeutics Corp. (KTTA)*
Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.
Pasithea is focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ket-a-mine infusions both in clinics and in-home settings.
Ket-a-mine is a U.S. Food and Dr-ug Administration (“FDA”) approved dr-ug introduced to the medical community as an anesthetic more than 50 years ago.
It has recently been repurposed for the treatment of psychiatric disorders using significantly lower doses than in anesthesia and is now gaining ground as a promising treatment for mental health disorders.
In certain psychiatric conditions, such as treatment-resistant depression (“TRD”) and post-traumatic stress disorder (“PTSD”), it has shown remarkable efficacy and a rapid and sustained effect, and up to 70% of those who receive this treatment can eventually show a clinical response.
#1 GAME-CHANGING POTENTIAL CATALYST - WEDNESDAY'S HUGE NEWS
As this news continues to circulate in the days ahead, it could become a huge catalyst for a potential vertical move.
Here's what you need to know:
Pasithea Therapeutics Launches In-Home Intravenous Ket-a-mine Therapy in Major U.S. Cities, Expanding its International Footprint
-- Pasithea Clinics to offer ket-a-mine infusion therapy for the treatment of mental health disorders --
-- First mobile clinics launch in New York City, Los Angeles, San Diego, and San Francisco, with expansion to additional U.S. cities in coming months --
-- Treatments conducted by board-certified medical professionals --
MIAMI BEACH, Fla., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its wholly owned subsidiary, Pasithea Clinics, commenced clinical operations, offering in-home intravenous (“IV”) ket-a-mine therapy to patients suffering from treatment-resistant mental health issues. Initially, the treatment will be offered in New York City, Los Angeles, San Diego, and San Francisco and will expand nationwide in the coming months.
“The need for more effective treatment options for patients with mental health disorders has never been greater. Ket-a-mine, when used at sub-anesthetic doses, has been shown to be highly effective in treating some psychiatric disorders. Still, we need to broaden access to this treatment to a larger patient population in a safe and convenient way. Through our mobile clinics, patients benefit from receiving the ket-a-mine therapy in the privacy and comfort of their own homes. With patient safety as our top priority, all ket-a-mine treatments will be delivered by board-certified medical professionals. This launch is an important stepping stone in expanding our international footprint in this space,” stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
Patients with mental health disorders often struggle to complete day-to-day activities, and even small tasks can take extra effort. In disorders such as depression and post-traumatic stress disorder, symptoms such as fatigue, social isolation, lack of motivation, and high levels of anxiety are frequent. The effort to go to a physical clinic can be overwhelming. By providing this treatment at the patient’s home, Pasithea aims to broaden access to this important therapy.
“We are pleased to commence our U.S. rollout in major cities in New York and California, with plans to scale our business in other cities over the coming months. Although ket-a-mine is a very safe dr-ug to administer, there are still some risks. Patient safety is of paramount importance, and we are providing a network of highly trained medical professionals to administer this treatment in the comfort of the patient´s home. Our medical team ensures that our patients receive state-of-the-art support throughout their treatment experience. We believe we can become the best-in-class and largest provider of IV ket-a-mine treatments in the United States. We will use our at-home model to expand our reach in the U.S. in a fast and accessible way,” said Dr. Adam Nadelson, Managing Director of Pasithea Clinics in the United States.
Read the full article here.
No. 2 KTTA Potential Catalyst - Low Float Profile
According to the Finviz.com website, KTTA has a low float.
The website reports this profile to have approximately 5.42Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.
No. 3 KTTA Potential Catalyst - Launching Of New UK Clinic
Pasithea Therapeutics Launches First Ket-a-mine Clinic In The UK
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a company in the psych-e-delics space, will launch its first U.K.-based ket-a-mine infusion clinic.
The company went public with a $24Mn IPO in the Nasdaq last month and is focused on research and discovery of new and effective treatments for psychiatric and neurological disorders.
What To Know: For the launch of its first U.K. clinic, Pasithea’s wholly-owned subsidiary, Pasithea Clinics, has partnered with ZEN Healthcare to offer intravenous ket-a-mine therapy to patients suffering from treatment-resistant mental health disorders.
The treatment will initially be offered in Knightsbridge, London, and is set to launch in October.
“We believe we can become the best-in-class provider of IV ket-a-mine treatments,” said Dr. Yassine Bendiabdallah, managing director of Pasithea Clinics in the U.K.
Why It's Important: Ket-a-mine, an FDA-approved anesthetic, has become widely used in an off-label capacity for the rapid treatment of depression symptoms. As scientists debate whether the dr-ug fits the category of a psych-e-delic substance, a number of for-profit actors are offering it as an alternative mental health treatment, showcasing very positive results.
“Evidence from dozens of trials over the past two decades consistently supports the efficacy of ket-a-mine in improving symptoms in some mental health disorders. We are thrilled to be able to provide this new treatment approach in the UK for those patients who are deemed eligible to receive it,” said Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
“We look forward to growing our specialty clinics network while we simultaneously progress with our dr-ug development program to move the needle forward for better mental health care,” Marques concluded.
Read the full article here.